Therapeutic Efficacy of Triple Combination of Metformin, DPP4 Inhibitor and Thiazolidinedione in Drug-naive Korean Type 2 Diabetic Patients
Phase of Trial: Phase IV
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Metformin (Primary) ; Sitagliptin (Primary) ; Thiazolidinediones (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 13 Sep 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 06 Oct 2017 Planned number of patients changed from 120 to 200.